Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has maintained an Overweight rating on Regeneron Pharmaceuticals but has lowered the price target from $1242 to $1195.
November 01, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Regeneron Pharmaceuticals but has lowered the price target from $1242 to $1195.
The maintenance of an Overweight rating suggests continued confidence in Regeneron's performance, but the lowered price target indicates some caution about future growth. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100